Search

Your search keyword '"Kay, Sigi"' showing total 29 results
Start Over Author "Kay, Sigi" Publication Year Range Last 10 years
29 results on '"Kay, Sigi"'

1. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study

Author

Ram, Ron, Hagin, David, Kikozashvilli, Nino, Freund, Tal, Amit, Odelia, Bar-On, Yael, Beyar-Katz, Ofrat, Shefer, Gabi, Moshiashvili, Miguel Morales, Karni, Chen, Gold, Ronit, Kay, Sigi, Glait-Santar, Chen, Eshel, Rinat, Perry, Chava, Avivi, Irit, Apel, Arie, Benyamini, Noam, Shasha, David, and Ben-Ami, Ronen

Published
2021
Full Text
View/download PDF

4. P651: REAL-WORLD EFFECTIVENESS OF VENETOCLAX-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN ISRAEL: UPDATE FROM THE MULTICENTER PROSPECTIVE REVEAL STUDY

Author

Herishanu, Yair, primary, Goldschmidt, Neta, additional, Itchaki, Gilad, additional, Bronstein, Yotam, additional, Levi, Itai, additional, Aviv, Ariel, additional, Fineman, Riva, additional, Dally, Najib, additional, Tadmor, Tamar, additional, Ronson, Aaron, additional, Abadi, Uri, additional, Shvidel, Levi, additional, Stemer, Galia, additional, Kay, Sigi, additional, Glait Santar, Chen, additional, Barak, Moran, additional, Rivlin, Noa, additional, Kaminsky, Natalie, additional, Cohen, Raanan, additional, Ofek, Keren, additional, Berelovich, Jenia, additional, Grunspan, Moshe, additional, and Benjamini, Ohad, additional

Published
2023
Full Text
View/download PDF

7. Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy—A Single Center Prospective Cohort Study

Author

Ram, Ron, primary, Freund, Tal, additional, Halperin, Tami, additional, Ben-Ami, Ronen, additional, Amit, Odelia, additional, Bar-On, Yael, additional, Beyar-Katz, Ofrat, additional, Eilaty, Nili, additional, Gold, Ronit, additional, Kay, Sigi, additional, Glait-Santar, Chen, additional, and Hagin, David, additional

Published
2022
Full Text
View/download PDF

8. Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis

Author

Soh, Kah Teong, primary, Came, Neil, additional, Otteson, Gregory E., additional, Jevremovic, Dragan, additional, Shi, Min, additional, Olteanu, Horatiu, additional, Natoni, Alessandro, additional, Lagoo, Anand, additional, Theakston, Edward, additional, Óskarsson, Jón Þórir, additional, Gorniak, Malgorzata, additional, Grigoriadis, George, additional, Arroz, Maria, additional, Fletcher, Matthew, additional, Lin, Pei, additional, Ludwig, Peter, additional, Tembhare, Prashant, additional, Matuzeviciene, Reda, additional, Radzevicius, Mantas, additional, Kay, Sigi, additional, Chen, Weina, additional, Cabrita, Carina, additional, and Wallace, Paul K., additional

Published
2022
Full Text
View/download PDF

10. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study

Author

Ram, Ron, primary, Grisariu, Sigal, additional, Shargian-Alon, Liat, additional, Amit, Odelia, additional, Bar-On, Yaeli, additional, Stepensky, Polina, additional, Yeshurun, Moshe, additional, Avni, Batia, additional, Hagin, David, additional, Perry, Chava, additional, Gurion, Ronit, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Gold, Ronit, additional, Glait-Santar, Chen, additional, Kay, Sigi, additional, and Avivi, Irit, additional

Published
2021
Full Text
View/download PDF

11. Toxicity and Efficacy of CAR-T in Patients with DLBCL Above the Age of 70 Years Compare to Younger Patients – a Matched Control Multi-Center Cohort Study

Author

Ram, Ron, primary, Grisariu, Sigal, additional, Shargian, Liat, additional, Amit, Odelia, additional, Bar-On, Yael, additional, Stepansky, Polina, additional, Yeshurun, Moshe, additional, Avni, Batia, additional, Hagin, David, additional, Perry, Chava, additional, Gurion, Ronit, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Gold, Ronit, additional, Kay, Sigi, additional, and Avivi, Irit, additional

Published
2021
Full Text
View/download PDF

12. Comprehensive Morphological Assessment of Cord Blood: Normal Values and the Prevalence of Morphologically Aberrant Leukocytes.

Author

Katz, Ben-Zion, Benisty, Dan, Kay, Sigi, Herzlich, Jacky, Raskind, Craig, and Marom, Ronella

Subjects
CORD blood, LEUCOCYTES, CELL anatomy, STEM cells, BASOPHILS
Abstract

Introduction: Cord blood (CB) is becoming a valuable source for stem cells utilized in a variety of cell therapy applications, as well as for newborn diagnostics. Some parameters of the CB cellular components can be provided by automated analyzers, while others, such as immature or aberrant cells, require blood film morphological assessment. The objectives of the study were to establish normal CB morphology and to determine the prevalence of morphologically aberrant leukocytes in CB. Methods: We performed a comprehensive morphological analysis of 100 CB samples taken from healthy term and appropriate-for-gestational-age neonates born to healthy mothers, preterm neonates, neonates of diabetic mothers, and small-for-gestational-age neonates. Blood counts were assessed, and manual morphological analyses were performed by laboratory specialists. Results: The manual differential count of normal CB samples established the following values: 47.8 ± 10.7% neutrophils, 31.2 ± 9.8% lymphocytes, 10.0 ± 4.0% monocytes, and 3.0 ± 2.5% eosinophils, with no significant sex-related differences. Blasts were observed in 44/100 samples with an average of 0.5 ± 0.7% per sample, and only a minor left shift was observed. There were significant populations of large granular lymphocytes (19.1 ± 10.6% of the total lymphocytes) and morphologically aberrant lymphocytes (12.4 ± 5.4% of the total lymphocytes) in the samples, irrespective of neonatal status. The differentials of preterm CB samples differ significantly from normal term CB samples, including the reverse of neutrophils/lymphocytes ratio, and the lack of basophils. Conclusions: Normal values and unique morphological features in the CB of neonates are described. The abundant morphologically aberrant lymphocytes in CB may represent an immature state of the immune system at birth. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

15. Front Cover

Author

Cipok, Michal, primary, Tomer, Aaron, additional, Elalamy, Ismail, additional, Kirgner, Ilya, additional, Dror, Naama, additional, Kay, Sigi, additional, and Deutsch, Varda R., additional

Published
2019
Full Text
View/download PDF

23. Flow Cytometry-based Detection of B-cell Lymphoproliferative Disorders in Patients with Mycosis Fungoides.

Author

GELLER, Shamir, KAY, Sigi, ELLENBOGEN, Eran, GOLDSMITH, Tomer, BAR-ON, Shoshi, WARSHAUER, Emily, DEUTSCH, Varda, SPRECHER, Eli, PERRY, Chava, and GOLDBERG, Ilan

Subjects
*LYMPHOPROLIFERATIVE disorders, *MYCOSIS fungoides, *CUTANEOUS T-cell lymphoma, *LYMPHOCYTIC leukemia, *BLOOD cell count, *CHRONIC lymphocytic leukemia, *CHRONIC leukemia
Abstract

The article presents several case studies related to flow Cytometry-based Detection of B-cell Lymphoproliferative Disorders in Patients with Mycosis Fungoides. Topics discussed a 61-year-old man was referred for evaluation of a non-pruritic rash that initially involved abdomen and later progressed to the back and limbs, and 59-year-old woman presented with a pruritic rash distributed over lateral aspects of her back and axilla with findings compatible with early-stage MF histopathologically.

Published
2020
Full Text
View/download PDF

29. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study.

Author

Ram R, Grisariu S, Shargian-Alon L, Amit O, Bar-On Y, Stepensky P, Yeshurun M, Avni B, Hagin D, Perry C, Gurion R, Sarid N, Herishanu Y, Gold R, Glait-Santar C, Kay S, and Avivi I

Subjects
Aged, Antigens, CD19, Cell- and Tissue-Based Therapy, Humans, Immunotherapy, Adoptive adverse effects, Middle Aged, Receptors, Antigen, T-Cell, Lymphoma, Follicular etiology, Lymphoma, Large B-Cell, Diffuse pathology, Receptors, Chimeric Antigen
Abstract

Data regarding efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in the elderly, geriatric population are insufficient. In 2019, tisagenlecleucel and axicabtagene-ciloleucel were commercially approved for relapsed/refractory diffuse large B-cell lymphoma. From May 2019 onwards, 47 relapsed/refractory diffuse large Bcell lymphoma patients, ≥70 years underwent lymphopharesis in three Israeli centers. Elderly (n=41, mean age 76.2 years) and young (n=41, mean age 55.4 years) patients were matched based on ECOG performance status and lactose dehydrogenase levels. There were no differences in CD4/CD8 ratio (P=0.94), %CD4 naive (P=0.92), %CD8 naive (P=0.44) and exhaustion markers (both HLA-DR and PD-1) between CAR-T cell products in both cohorts. Forty-one elderly patients (87%) received CAR-T cell infusion. There were no differences in the incidence of grade ≥3 cytokine-release-syndrome (P=0.29), grade≥3 neurotoxicity (P=0.54), and duration of hospitalization (P=0.55) between elderly and younger patients. There was no difference in median D7-CAR-T cell expansion (P=0.145). Response rates were similar between the two groups (complete response 46% and partial response 17% in the elderly group, P=0.337). Non-relapse mortality at 1 and 3 months was 0 in both groups. With a median follow-up of 7 months (range, 1.3-17.2 months), 6- and 12-months progression-free and overall survival in elderly patients were 39% and 32%, and 74% and 69%, respectively. EORTC QLQ-C30 questionnaires, obtained at 1 month, showed worsening of disability and cancer-related-symptoms in elderly versus younger patients. We conclude that outcomes of CAR-T cell therapy are comparable between elderly, geriatric and younger patients, indicating that age as per se should not preclude CAR-T cell administration. Longer rehabilitation therapy is essential to improve disabilities and long-term symptoms.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results